CA3233157A1 - Combination therapies using prmt5 inhibitors for the treatment of cancer - Google Patents

Combination therapies using prmt5 inhibitors for the treatment of cancer Download PDF

Info

Publication number
CA3233157A1
CA3233157A1 CA3233157A CA3233157A CA3233157A1 CA 3233157 A1 CA3233157 A1 CA 3233157A1 CA 3233157 A CA3233157 A CA 3233157A CA 3233157 A CA3233157 A CA 3233157A CA 3233157 A1 CA3233157 A1 CA 3233157A1
Authority
CA
Canada
Prior art keywords
alkyl
cancer
hydrogen
methyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233157A
Other languages
English (en)
French (fr)
Inventor
Peter Olson
Lars Daniel ENGSTROM
James Gail Christensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of CA3233157A1 publication Critical patent/CA3233157A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3233157A 2021-10-06 2022-10-06 Combination therapies using prmt5 inhibitors for the treatment of cancer Pending CA3233157A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252995P 2021-10-06 2021-10-06
US63/252,995 2021-10-06
PCT/US2022/045895 WO2023059795A1 (en) 2021-10-06 2022-10-06 Combination therapies using prmt5 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA3233157A1 true CA3233157A1 (en) 2023-04-13

Family

ID=84053165

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233157A Pending CA3233157A1 (en) 2021-10-06 2022-10-06 Combination therapies using prmt5 inhibitors for the treatment of cancer

Country Status (10)

Country Link
US (1) US20240398795A1 (https=)
EP (1) EP4412607A1 (https=)
JP (1) JP2024538719A (https=)
KR (1) KR20240095421A (https=)
CN (1) CN118251218A (https=)
AU (1) AU2022360837A1 (https=)
CA (1) CA3233157A1 (https=)
IL (1) IL311663A (https=)
MX (1) MX2024004171A (https=)
WO (1) WO2023059795A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023202626A1 (zh) * 2022-04-22 2023-10-26 北京望实智慧科技有限公司 稠和哒嗪酮化合物作为prmt5抑制剂
CN119301101A (zh) * 2022-07-29 2025-01-10 四川科伦博泰生物医药股份有限公司 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0922332D0 (en) * 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
EP3177288A4 (en) * 2014-08-04 2018-04-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3191592A1 (en) * 2014-09-11 2017-07-19 Novartis AG Inhibition of prmt5 to treat mtap-deficiency-related diseases
TW202122387A (zh) 2019-09-12 2021-06-16 美商米瑞替療法公司 Mta協同性之prmt5抑制劑
AU2020410418A1 (en) * 2019-12-18 2022-06-09 Pfizer Inc. Once daily cancer treatment regimen with a PRMT5 inhibitor
WO2021138578A1 (en) * 2019-12-31 2021-07-08 The Trustees Of Indiana University Repurposing fda-approved drugs as a novel cancer therapeutic avenue through inhibition of prmt5

Also Published As

Publication number Publication date
IL311663A (en) 2024-05-01
JP2024538719A (ja) 2024-10-23
CN118251218A (zh) 2024-06-25
MX2024004171A (es) 2024-04-23
EP4412607A1 (en) 2024-08-14
WO2023059795A1 (en) 2023-04-13
AU2022360837A1 (en) 2024-04-18
KR20240095421A (ko) 2024-06-25
US20240398795A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
CA3214530A1 (en) Combination therapies using prmt5 inhibitors for the treatment of cancer
CA3214535A1 (en) Combination therapies using prmt5 inhibitors for the treatment of cancer
ES3004338T3 (en) Combination therapies
CN107213466B (zh) 一种柱芳烃类复合物、其制备方法、药物组合物和用途
KR20200140274A (ko) 4'-할로겐 함유 뉴클레오티드 및 뉴클레오시드 치료 조성물 및 이와 관련된 용도
AU2017220738A1 (en) Carboxamide derivatives useful as RSK inhibitors
CA3233157A1 (en) Combination therapies using prmt5 inhibitors for the treatment of cancer
AU2023334579A1 (en) Combination therapies using prmt5 inhibitors and bcl-2 family inhibitors for the treatment of cancer
CA2980885A1 (en) Glycolipids and pharmaceutical compositions thereof for use in therapy
JP2021527064A (ja) Ｐｒｃ１阻害剤及びそれを用いた治療方法
WO2025217015A1 (en) Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer
EA051338B1 (ru) Комбинированная терапия с использованием ингибиторов prmt5 для лечения рака
WO2025217007A1 (en) Combination therapies using prmt5 inhibitors and immune checkpoint inhibitors for the treatment of cancer
CN117769420A (zh) 使用prmt5抑制剂治疗癌症的组合疗法
CN117769421A (zh) 使用prmt5抑制剂治疗癌症的组合疗法
WO2025217008A1 (en) Combination therapies using prmt5 inhibitors and sos1 inhibitors for the treatment of cancer
CA2848724A1 (en) Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240905

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240905

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20250520

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20250520

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250522

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250825

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250825

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250825

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250902

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250902

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251118

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251118

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260206

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260209